

# SECURITIES AND EXCHANGE COMMISSION

## Washington, D.C. 20549

### SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

OPUS GENETICS, INC.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

00887A204

(CUSIP Number)

05/05/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

### SCHEDULE 13G

CUSIP No. 00887A204

1	<b>Names of Reporting Persons</b> BIOS FUND III, LP
2	<b>Check the appropriate box if a member of a Group (see instructions)</b> <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	<b>Sec Use Only</b>
4	<b>Citizenship or Place of Organization</b> DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 430,665.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 430,665.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 430,665.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 0.7 %	
12	Type of Reporting Person (See Instructions) PN	

**Comment for Type of Reporting Person:** Percentage based on 59,661,197 shares of the Issuer's common stock, par value \$0.0001 per share ("Shares") outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.	00887A204
-----------	-----------

1	Names of Reporting Persons BIOS FUND III QP, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,801,953.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,801,953.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,801,953.00	

10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 4.7 %
12	Type of Reporting Person (See Instructions) PN

**Comment for Type of Reporting Person:** Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.	00887A204
-----------	-----------

1	Names of Reporting Persons BIOS FUND III NT, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 450,811.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 450,811.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 450,811.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 0.8 %	
12	Type of Reporting Person (See Instructions) PN	

**Comment for Type of Reporting Person:** Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.

00887A204

1	Names of Reporting Persons BIOS EQUITY PARTNERS III, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.2 %	
12	Type of Reporting Person (See Instructions) PN	

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds (defined below). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of each of Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT") (collectively, the "Bios III Funds"), and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.

00887A204

1	Names of Reporting Persons CAVU MANAGEMENT, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	

3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.2 %	
12	Type of Reporting Person (See Instructions) PN	

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.	00887A204
-----------	-----------

1	Names of Reporting Persons BIOS CAPITAL MANAGEMENT, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power

		0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.2 %	
12	Type of Reporting Person (See Instructions) IA, PN	

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.	00887A204
-----------	-----------

1	Names of Reporting Persons CAVU ADVISORS, LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9)	

	6.2 %
12	Type of Reporting Person (See Instructions) OO

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.	00887A204
-----------	-----------

1	Names of Reporting Persons BIOS ADVISORS GP, LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.2 %	
12	Type of Reporting Person (See Instructions) OO	

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.

00887A204

1	Names of Reporting Persons LESLIE WAYNE KREIS, JR.	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.2 %	
12	Type of Reporting Person (See Instructions) IN	

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

CUSIP No.

00887A204

1	Names of Reporting Persons AARON GLENN LOUIS FLETCHER
---	--



2	Check the appropriate box if a member of a Group (see instructions)	
	<input type="checkbox"/> (a)	<input checked="" type="checkbox"/> (b)
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.2 %	
12	Type of Reporting Person (See Instructions) IN	

**Comment for Type of Reporting Person:** Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.

Percentage based on 59,661,197 Shares outstanding as of May 12, 2025, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

## SCHEDULE 13G

### Item 1.

(a) Name of issuer:

OPUS GENETICS, INC.

(b) Address of issuer's principal executive offices:

8 Davis Drive Durham, NC, 27713

### Item 2.

(a) Name of person filing:

This Schedule 13G is being jointly filed by: Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Equity III, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors, Mr. Kreis, and Dr. Fletcher.

(b) Address or principal business office or, if none, residence:

1751 River Run #400 Fort Worth, TX 76107

(c) Citizenship:

Item 2(A) is incorporated herein by reference.

(d) **Title of class of securities:**  
Common Stock, \$0.0001 par value per share

(e) **CUSIP No.:**  
00887A204

**Item 3.** If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4.** **Ownership**

- (a) **Amount beneficially owned:**  
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
- (b) **Percent of class:**  
The information contained in Item 11 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4. %
- (c) **Number of shares as to which the person has:**
  - (i) **Sole power to vote or to direct the vote:**  
The information contained in Item 5 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
  - (ii) **Shared power to vote or to direct the vote:**  
The information contained in Item 6 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
  - (iii) **Sole power to dispose or to direct the disposition of:**  
The information contained in Item 7 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
  - (iv) **Shared power to dispose or to direct the disposition of:**  
The information contained in Item 8 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

**Item 5.** **Ownership of 5 Percent or Less of a Class.**

**Item 6.** **Ownership of more than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not Applicable

**Item 8. Identification and Classification of Members of the Group.**

Not Applicable

**Item 9. Notice of Dissolution of Group.**

Not Applicable

**Item 10. Certifications:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**BIOS FUND III, LP**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

**BIOS FUND III QP, LP**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

**BIOS FUND III NT, LP**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

**BIOS EQUITY PARTNERS III, LP**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

**CAVU MANAGEMENT, LP**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

**BIOS CAPITAL MANAGEMENT, LP**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

**CAVU ADVISORS, LLC**

Signature: John Fucci  
Name/Title: Attorney-in-Fact  
Date: 08/11/2025

## BIOS ADVISORS GP, LLC

Signature: John Fucci

Name/Title: Attorney-in-Fact

Date: 08/11/2025

## LESLIE WAYNE KREIS, JR.

Signature: John Fucci

Name/Title: Attorney-in-Fact

Date: 08/11/2025

## AARON GLENN LOUIS FLETCHER

Signature: John Fucci

Name/Title: Attorney-in-Fact

Date: 08/11/2025

### Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

Exhibit 99.2 - Power of Attorney

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, par value \$0.0001, of Opus Genetics, Inc. a Delaware corporation (the "Issuer"), unless and until a Reporting Person shall give written notice to the other Reporting Persons that it wishes to make separate Schedule 13G filings.

The undersigned further agree that each party hereto is responsible for timely filing of such Statement on Schedule 13G and any further amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, provided that no party is responsible for the completeness and accuracy of the information concerning the other party, unless such party knows or has reason to believe that such information is inaccurate. The undersigned further agree that this Agreement shall be included as an Exhibit to such joint filing.

This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Joint Filing Agreement to be duly executed effective as of October August 10, 2025.

Dated: August 10, 2025

**BIOS FUND III, LP**

By: Bios Equity Partners III, LP,  
its general partner

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

---

**BIOS FUND III QP, LP**

By: Bios Equity Partners III, LP,  
its general partner

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

**BIOS FUND III NT, LP**

By: Bios Equity Partners III, LP,  
its general partner

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

---

**BIOS EQUITY PARTNERS III, LP**

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

**CAVU MANAGEMENT, LP**

By: Cavu Advisors, LLC,  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

**BIOS CAPITAL MANAGEMENT, LP**

By: Bios Advisors GP, LLC  
its general partner

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

**CAVU ADVISORS, LLC**

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

**BIOS ADVISORS GP, LLC**

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

---

**LESLIE WAYNE KREIS, JR.**, in his individual capacity

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

**AARON GLENN LOUIS FLETCHER.**, in his individual capacity

By: /s/ John Fucci  
John Fucci, Attorney-in-Fact

---



**POWER OF ATTORNEY**

The undersigned hereby removes the following authority from Daniel Schwarz and, in his place, constitutes and appoints John Fucci and Troy Osborn, the lawful attorneys-in-fact and agents with full power and authority to execute and file on the undersigned's behalf, any and all instruments including Forms 3, 4 and 5, and Schedules 13D, 13G and 13F (collectively, the "Filings"), and any amendments, supplements or successor forms thereto pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any rules or regulations or requirements of the Securities and Exchange Commission in connection with the undersigned's reporting obligations with respect to securities of Opus Genetics, Inc., a Delaware corporation, pursuant to Section 13 of the Exchange Act and Section 16 of the Exchange Act.

The authority of such attorneys-in-fact shall continue until the undersigned is no longer required to file any of the Filings, unless earlier revoked in writing. The undersigned hereby ratifies, confirms and approves in all respects all Filings (including amendments thereto) and actions taken by any of the attorneys-in-fact relating to such Filings.

The undersigned acknowledges that the attorneys-in-fact are not assuming any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act.

IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.

Dated: May 22, 2025

**BIOS FUND III, LP**

By: Bios Equity Partners III, LP,  
its general partner

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ Leslie Wayne Kreis, Jr.  
Leslie Wayne Kreis, Jr., Manager

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ Aaron Glenn Louis Fletcher  
Aaron Glenn Louis Fletcher, Manager

**BIOS FUND III QP, LP**

By: Bios Equity Partners III, LP,  
its general partner

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ Leslie Wayne Kreis, Jr.  
Leslie Wayne Kreis, Jr., Manager

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ Aaron Glenn Louis Fletcher  
Aaron Glenn Louis Fletcher, Manager

**BIOS FUND III NT, LP**

By: Bios Equity Partners III, LP,  
its general partner

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ Leslie Wayne Kreis, Jr.  
Leslie Wayne Kreis, Jr., Manager

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ Aaron Glenn Louis Fletcher  
Aaron Glenn Louis Fletcher, Manager

---

**BIOS EQUITY PARTNERS III, LP**

By: Cavu Management, LP,  
its general partner

By: Cavu Advisors, LLC,  
its general partner

By: /s/ Leslie Wayne Kreis, Jr.  
Leslie Wayne Kreis, Jr., Manager

By: Bios Capital Management, LP,  
its general partner

By: Bios Advisors GP, LLC,  
its general partner

By: /s/ Aaron Glenn Louis Fletcher  
Aaron Glenn Louis Fletcher, Manager

**CAVU MANAGEMENT, LP**

By: Cavu Advisors, LLC,  
its general partner

By: /s/ Leslie Wayne Kreis, Jr.  
Leslie Wayne Kreis, Jr., Manager

**BIOS CAPITAL MANAGEMENT, LP**

By: Bios Advisors GP, LLC  
its general partner

By: /s/ Aaron Glenn Louis Fletcher  
Aaron Glenn Louis Fletcher Manager

**CAVU ADVISORS, LLC**

By: /s/ Leslie Wayne Kreis, Jr.  
Leslie Wayne Kreis, Jr., Manager

**BIOS ADVISORS GP, LLC**

By: /s/ Aaron Glenn Louis Fletcher  
Aaron Glenn Louis Fletcher, Manager

/s/ Leslie Wayne Kreis, Jr.

**LESLIE WAYNE KREIS, JR.**, in his individual capacity

/s/ Aaron Glenn Louis Fletcher

**AARON GLENN LOUIS FLETCHER**, in his individual capacity

---